AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JAN 7 - (NewsRx.com & NewsRx.net) -- The hepatitis A vaccine did not promote atherogenesis in a murine model.
According to recent research from the United States, "Our laboratory demonstrated that seropositivity to hepatitis A virus (HAV) independently predicts risk for coronary artery disease (CAD). As these findings are based only on the presence of HAV-specific antibodies and not infectious virus, this prompted questions regarding possible effects of HAV vaccines on CAD development."
"If seropositivity to HAV alone, resulting from HAV vaccination, leads to increased atherogenesis, this raises important issues regarding the benefit of protection against HAV infection vs the risk of developing CAD," said Mary Susan Burnett and colleagues at the MedStar Research Institute. "This study examines the effect of HAV vaccination on atherosclerosis development in a cholesterol-fed mouse model. Animals either received HAV vaccine, adjuvant, or saline. After 15 weeks, no significant differences were found in lesion area between the groups: HAV vaccine, 13,470 micrometer[superscript]2; adjuvant, 16,332 micrometer[superscript]2; and ...
Source: HighBeam Research, Hepatitis A vaccine does not promote atherogenesis in murine model.